ResMed (RMD) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
6 Nov, 2026Executive summary
Annual meeting scheduled for Nov. 18, 2026, at 3:00 p.m. US Pacific Time and Nov. 19 at 10:00 a.m. Australian Eastern Time, via live webcast.
Agenda covers election of 10 directors, auditor ratification for FY ending June 30, 2027, and an advisory vote on named executive officer compensation.
Voting matters and shareholder proposals
Board recommends voting For all three matters: director elections, PwC LLP auditor ratification, and advisory approval of named executive officer compensation.
Board of directors and corporate governance
Ten nominees—Carol Burt, Jan De Witte, Christopher DelOrefice, Karen Drexler, Michael Farrell, Peter Farrell, Harjit Gill, John Hernandez, Nicole Mowad-Nassar, and Desney Tan—are nominated to serve until the 2027 annual meeting and until successors are elected and qualified.
Latest events from ResMed
- Strong FY26 performance funds growth and returns as board and auditor leadership transition.RMD
Proxy filing - Revenue rose 7% core CC, EPS 14%, and shareholder returns topped $1.0B.RMD
Q1 2027 - Shareholders were asked to elect 10 directors, ratify KPMG, and approve executive pay.RMD
Proxy Filing - Ten director elections, KPMG ratification, and advisory votes anchor the ballot.RMD
Proxy Filing - Board backs all three proposals: elect 11 directors, ratify KPMG and approve say-on-pay.RMD
Proxy Filing - Board backs all agenda items, including 11 director nominees and two employee plan amendments.RMD
Proxy Filing - 2026 saw strong growth, strategic investments, and enhanced sustainability and governance.RMD
Stewardship presentation - FY26 saw 8% revenue growth, 16% EPS growth, and $1B returned to shareholders.RMD
Corporate presentation - Volume-driven growth, digital engagement, and portfolio shifts drive robust outlook.RMD
Morgan Stanley 24th Annual Global Healthcare Conference